Aurora-A kinase-inactive mutants disrupt the interaction with Ajuba and cause defects in mitotic spindle formation and G2/M phase arrest in HeLa cells

Meirong Bai*, Jun Ni*, Suqin Shen, Qiang Huang, Jiaxue Wu, Yichen Le & Long Yu*
State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, 220 Handan Road, Shanghai, People's Republic of China

Aurora-A is a centrosome-localized serine/threonine kinase that is overexpressed in multiple human cancers. We previously reported an intramolecular inhibitory regulation of Aurora-A between its N-terminal regulatory domain (Nt, amino acids [aa] 1-128) and the C-terminal catalytic domain (Cd, aa 129-403). Here, we demonstrate that although both Aurora-A mutants (AurA-K250G and AurA-D294G/Y295G) lacked interactions between the Nt and Cd, they also failed to interact with Ajuba, an essential activator of Aurora-A, leading to loss of kinase activity. Additionally, overexpression of either of the mutants resulted in centrosome amplification and mitotic spindle formation defects. Both mutants were also able to cause G2/M arrest and apoptosis. These results indicate that both K250 and D294/Y295 are critical for direct interaction between Aurora-A and Ajuba and the function of the Aurora-A complex in cell cycle progression. [BMB Reports 2014; 47(11): 631-636]

INTRODUCTION

Aurora-A is a serine/threonine kinase in the Aurora kinase family, which includes members involved in regulating centrosome function, bipolar spindle assembly, and chromosome segregation processes (1). Aurora-A localizes to centrosomes and spindle microtubules proximal to centrosomes during mitosis (2). The expression and the activity of Aurora-A kinase are regulated in a cell cycle-dependent manner; levels are low in G1/S, upregulated during G2/M, and rapidly reduced after mitosis (3). The ectopic overexpression of Aurora-A induces oncogenic transformation (4, 5), and inhibition of Aurora kinase activity in mammalian cells leads to abnormal cell growth and polyploidy centrosome dysfunction (6-8). Thus, the Aurora kinases may be good molecular therapeutic targets for cancer.

Aurora-A kinase has a C-terminal catalytic domain (Cd) that is highly conserved within the Aurora kinase family and is regulated by phosphorylation in a cell cycle-dependent manner. This phosphorylation, which is required for kinase activity, occurs on a conserved residue, threonine 288, within the activation loop (aa 274-299) of the kinase’s catalytic domain and significantly increases enzymatic activity. Aurora-A’s kinase activity is regulated by one or more unknown kinases (9) and by association with the activators Ajuba (10), human enhancer of filamentation 1 (HEF1) (11), targeting protein for Xklp2 (TPX2) (12), etc.

We previously reported an intramolecular inhibitory regulation of Aurora-A between its N-terminal regulatory domain (Nt, aa 1-128) and the Cd (aa 129-403). The non-Aurora box (aa 64-128) in the Nt maintains Aurora-A in an auto-inhibited conformation to prevent phosphorylation and activation of the Cd in unstimulated cells. Once other proteins bind the Aurora box, the inhibitory conformation opens or becomes more closed, depending on the structure and function of the binding proteins (13).

We performed mutational analysis and found that two mutations (AurA-K250G, AurA-D294G/Y295G) in the conserved acidic aa residues in the Cd of Aurora-A both abolished the interaction of the Nt and Cd. However, kinase activity did not increase according to the auto-inhibitory model of Aurora-A. Furthermore, these mutations also abolished the interaction between Aurora-A and Ajuba. Overexpression of either mutant caused abnormal centrosome characteristics and G2/M arrest in HeLa cells. These results indicate that the mutation of these residues affects the direct interaction of Aurora-A and Ajuba to cause abnormal cell division.
RESULTS

The Aurora-A mutants (AurA-K250G and AurA-D294GY295G) abolish the Nt and Cd interaction

We previously determined that the Nt domain of Aurora-A binds (aa 1-128) to the Cd (aa 129-403). Computer modeling studies predicted that four residues might affect the interaction between the Nt and Cd. Arg246 (R246), Lys250 (K250), Arg255 (R255), and Asp294-Tyr295 (D294-Y295) are all located within or near the Aurora-A activation loop. Each of these residues was independently mutated to Gly to determine whether any of these amino acids affect the Nt-Cd interaction.

We examined whether the R246G, K250G, R255G, and D294GY295G mutants affected the binding ability of Nt and Cd. 293T cells were transfected with Myc-tagged Cd and Myc-tagged Cd mutants separately, and lysates from these cells were incubated with purified glutathione (GST)-Nt fusion proteins or GST and then subjected to immunoblotting analysis with anti-Myc antibody to reveal any coprecipitation. The results showed that Myc-Aur-A-R246G and Myc-Aur-A-R255G could bind to GST-Aurora-A-Nt similarly to Myc-Aurora-A but not to GST. However, Aur-A-K250G and Aur-A-D294GY295G mutants failed to interact with Aurora-A Nt (Fig. 1). This result strongly demonstrated that the two mutated residues, K250G and D294GY295G, contribute to the interaction between the Nt and Cd.

The Aurora-A mutants fail to bind to Ajuba and reduce kinase activity

We found that the Aurora-A mutants (AurA-K250G and AurA-D294GY295G) affected the binding ability of the Nt (aa 1-128) and Cd (aa 129-403). Next, we examined whether these mutants influenced kinase activity.

The recombinant mutant kinases were assayed to determine whether their kinase activity toward myelin basic protein (MBP) was affected. Fig. 2A shows that mutants Aur-A-K250G and Aur-A-D294GY295G did not exhibit kinase activity, which is consistent with the results obtained with the kinase-dead form (K162R) of Aurora-A.

The phosphorylation of Aurora-A on Thr288 occurred during the G2-M phase, which is coincident with enzymatic activation. The phosphorylation of Thr288 thus provides an index of Aurora-A enzymatic activation. Given that Thr288 phosphorylation appears to be critical for Aurora-A kinase activity, we further determined whether the mutation would influence the autophosphorylation of Aurora-A on Thr288. We purified His-tagged wild-type Aurora-A and the mutants from Escherichia coli and examined the phosphorylation state of Thr288 by immunoblot analysis with an antibody specific for Aurora-A phosphorylated on this residue (T288P). His-tagged Aurora-A, which is highly phosphorylated, was detected on the T288P blot, whereas Aur-A-K250G and Aur-A-D294GY295G were not, similar to the kinase-inactive mutant Aur-A-K162R (Fig. 2B).

Ajuba was identified as a binding protein of Aurora-A, and the Aurora-A-Ajuba interaction contributes to the autophosphorylation and consequent activation of Aurora-A (10). Given that Ajuba appears to be required for the activation of Aurora-A, we next examined whether Ajuba influenced the activity of Aurora-A mutants. 293T cells were co-transfected with hemagglutinin (HA)-tagged Ajuba and Myc-tagged Aurora-A mutants (Aur-A-K250G, Aur-A-D294GY295G). Cell lysates were subjected to immunoblot analysis with an anti-T288P antibody. As shown in Fig. 2C, Ajuba enhanced the autophosphorylation of WT Aurora-A but did not affect Aur-A-K250G and Aur-A-D294GY295G, in which the mutation sites lie in or near the activation loop of Aurora-A. So can K250G and D294GY295G mutants maintain the interaction with Ajuba? To answer this question, we performed in vitro GST-pull down assays. Lysates from 293T cells expressing Myc-tagged Ajuba and GST fusion Aurora-A mutants were analyzed for their binding. Only direct binding of Ajuba with Aurora-A (WT) was observed (Fig. 2D). Moreover, immunoprecipitation assays were employed to assess the association of Ajuba with Aurora-A or the mutants in vivo. Consistently, when immunoprecipitated with anti-Myc antibody, endogenous Ajuba was only detected in the immunoprecipitated complex from Myc-Aurora-A-transfected cells (Fig. 2E). Taken together, the results indicate that both mutants affected the interaction between Ajuba and Aurora-A and abolished the autophosphorylation and consequent activation of Aurora-A.
Fig. 2. The Aurora-A mutants lack kinase activity and fail to interact with Ajuba. (A) 293T cells were transfected with expression plasmids for wild-type (WT) Myc-Aurora-A, Myc-K250G, or Myc-D294G/Y295G. The kinase-dead mutant Myc-K162R was used as a control. After 48 h, cell lysates were immunoprecipitated (IP) with an anti-Myc antibody. Aliquots of the immunoprecipitates were probed with an anti-Myc antibody (top panels) and subjected to in vitro kinase assays with MBP and [\(\gamma\)-32P] ATP as substrates. Aliquots of immunoprecipitates were separated by 12% SDS-PAGE followed by autoradiography. HC indicates antibody heavy chain. (B) The mutants influenced autophosphorylation of Aurora-A on Thr288. His-tagged WT Aurora-A and the mutants expressed from E. coli were examined for the phosphorylation state of Thr288 by immunoblot analysis with an antibody specific for Aurora-A phosphorylation on this residue (T288P). (C) Ajuba could not induce Aurora-A mutant autophosphorylation on Thr288. Myc-tagged Aurora-A, Myc-K250G, Myc-D294G/Y295G, or Myc-K162R were coexpressed with the indicated concentrations of HA-Ajuba. After 48 h, the lysates were collected, and the extent of Aurora-A phosphorylation was determined by immunoblot analysis with a T288P antibody. pEGFP-C1 cotransfection served as a control for transfection efficiency, and GFP levels were assessed using anti-GFP antibodies. (D) AurA-K250G, AurA-D294G/Y295G mutants abolished Ajuba binding. Cells expressing Ajuba were incubated with purified GST alone, GST-Aurora-A, or GST-Aurora-A mutants pre-bound to GST agarose beads. These beads were lysed and analyzed by western blotting. Ajuba bound to GST-Aurora-A but not to GST-tag or the mutants. (E) Neither Aur-A-D294G/Y295G nor Aur-A-K250G could interact with Ajuba in vivo. 293T cells were transfected to transiently express Myc-Aurora-A, Myc-Aurora-A-D294G/Y295G, or Myc-Aurora-A-K250G. After 48 h, the cell lysates were immunoprecipitated (IP) with anti-Myc agarose, and the precipitates were subjected to immunoblot analysis with either anti-Myc or anti-Ajuba antibody.

Fig. 3. Overexpression of either mutant results in abnormal mitotic spindle formation. (A) Representative immunofluorescence images of HeLa cells. Synchronized HeLa cells were transfected with Myc, Myc-Aurora-A, Myc-K250G, or Myc-D294G/Y295G between the two thymidine blocks. Cells were subjected to immunofluorescence microscopy 9 h after release. Overlapped images were obtained from cells labeled with an anti-\(\gamma\)-tubulin mouse antibody (tubulin, red) and DAPI (DNA, blue). (B) The percentage of spindle structures was averaged from three independent experiments, and at least 100 spindle structures were counted. The p values demonstrate a significant difference between the control and mutant-transfected cells for the incidence of abnormal spindles. **P < 0.01.

Overexpression of either mutant leads to defects in mitotic spindle formation
As Aurora-A is involved in the regulation of centrosome function, bipolar spindle assembly, and chromosome segregation processes, the effects of the mutants on spindle organization and chromosome alignment were explored using immunofluorescence labeling. HeLa cells were transfected with Myc-tagged Aurora-A (WT), AurA-K250G, or Aur-A-D294G/Y295G mutants, and pCMV-Myc was used as a control. HeLa cells were synchronized by double treatment with thymidine to enrich G2/M phase cells and then harvested for immunofluorescence analysis. The Myc- or Myc-Aurora-A-transfected
cells displayed normal bipolar mitotic spindles. However, cells that overexpressed either AurA-K250G or AurA-D294G/Y295G mutants showed a variety of spindle organization defects, including multipolarity, severe chromosome alignment defects, or centrosome amplification (Fig. 3A). The percentages of cells with abnormal mitotic spindles were quantified (Fig. 3B). Control samples only displayed 3% abnormal mitotic spindles, whereas the mutant-transfected cells exhibited about 20% abnormal mitotic spindles, which is consistent with a known Aurora-A inhibition phenotype (14, 15).

**Overexpression of either mutant induces G2/M arrest and apoptosis**

Previous findings implied the involvement of Aurora-A in regulating cell cycle progression. To explore the roles of the mutants in cell cycle regulation, Myc-tagged Aurora-A (WT), AurA-K250G, or AurA-D294G/Y295G plasmids were transfected with the pBB14-GFP plasmid into HeLa cells. The population percentage of HeLa cells transfected with control vector was 8.26% in the G2/M phase, and it decreased to 6.65% when transfected with Myc-Aurora-A (WT), which could promote cell cycle progression. However, we observed increases in G2/M populations in HeLa cells that were transfected with either AurA-K250G or AurA-D294G/Y295G plasmids (18.77%, 18.12%) compared with control (8.26%) (Fig. 4A). The results imply that both mutants are able to induce arrest in the G2/M phase.

In addition, it has been reported that treatment with an Aurora-A kinase inhibitor causes apoptosis. Therefore, we carried out a standard cell apoptosis assay by labeling cells with Annexin V. Myc-tagged Aurora-A (WT), AurA-K250G, or AurA-D294G/Y295G plasmids were transfected with the pBB14-GFP plasmid into HeLa cells and subjected to Annexin V analysis.

**Fig. 4.** Overexpression of either mutant increases G2/M populations and causes apoptosis. (A) Control, Aurora-A (WT) or mutant plasmids were cotransfected with pBB14-GFP plasmid into HeLa cells. After 48 h, cells were harvested, and the percentages of cells in individual cell cycle phases were determined by flow cytometry. The pCMV-Myc vector was used as a control. Values are given as mean ± SD; n=3. **P < 0.01. Cells described in panel A and B were analyzed by western blot using a Myc antibody, β-Actin was used as a loading control. (B) Annexin V analysis showed that both mutants exerted an apoptotic effect. Apoptosis was calculated as the percentage of Annexin V-positive and 7-AAD-negative cells compared to the total number of cells and is shown as mean ± SD; n = 3.
Aurora-A is a centrosome kinase that contributes to the regulation of mitosis. The initial activation of Aurora-A in the late G2 phase of the cell cycle requires interaction with Ajuba. Previously, we found that the Nt can inhibit C-terminal kinase activity both in vitro and in vivo via a direct interaction. In this study, we characterized two Aurora-A mutants, K250G and D294G/Y295G. We found that mutation of the conserved amino acid residues in the acidic patch on Aurora-A abolished the binding of the Nt to Cd. We speculated that the mutant kinase activity should increase because the Nt's inability to bind to the Cd of the mutants would open the inhibitory conformation, resulting in increased kinase activity. However, the kinase activities of Aurora-A mutants did not increase according to the autoradiography model. Additionally, we found that the mutants lost their ability to bind to Ajuba, which is required for Aurora-A activation; this is probably the reason why both mutants lost their kinase activity. Furthermore, overexpression of either of the Aurora-A mutants (AurA-K250G and AurA-D294G/Y295G) severely disturbed mitotic spindle formation and resulted in G2/M arrest and apoptosis in HeLa cells.

How could the expression of the Aurora-A mutants (AurA-K250G and AurA-D294G/Y295G) mediate defects in mitotic spindle formation? Aurora-A has crucial roles in mitotic spindle formation and centrosome maturation. Several reports have demonstrated that Aurora-A can interact with and regulate the activities of many important cellular proteins associated with cell cycle and cell division, including Ajuba, TPX2, HEF1, PAK, cyclin B, and Cdc2 (16). Although we have demonstrated that the K250 and D294/Y295 residues are crucial for the interaction between Ajuba and Aurora-A, it remains to be determined whether the mutants could affect the interaction of Aurora-A with other activators or substrates. Overexpression of either of the mutants may result in competitive binding with the activators or substrates of the endogenous Aurora-A, leading to abnormalities in spindle or centrosome regulation.

Why did mutation of K250 and D294/Y295 affect Aurora-A's binding to Ajuba and its activation? An obvious explanation may be that mutation of Asp294 and Tyr295, which lie in the activation loop of Aurora-A, may induce the conformational change of Aurora-A and result in the failure of Ajuba binding. Although Lys250 is not in the activation loop, this residue is particularly close to His280 and Pro282, which appear to be the pivot points of the conformational change of the activation loop (17). A small change at the pivot points (H280, P282) could result in a large conformational change and impair Ajuba binding, which is required for Aurora-A activation.

In summary, we firstly identified the distinct sites that are essential for Aurora-A activity. Our data provide a better understanding of Aurora-A regulation and offer insight into the development of specific small molecule inhibitors (18).

**MATERIALS AND METHODS**

Materials and Methods were provided in Supplementary data: http://www.bmbreports.org/mbmb_by_volume.html?vol=47.

**Cell culture, synchronization, and transfection**

293T and HeLa cells were cultured in DMEM (Gibco-BRL/Life Technologies, Carlsbad, CA, USA), which was supplemented with 10% (v/v) fetal calf serum (Gibco-BRL) at 37°C in 5% CO₂-humidified atmosphere. HeLa cells were blocked for 20 h with thymidine (final concentration 2 mM), washed three times with phosphate-buffered saline (PBS) and then incubated with fresh medium. After 8 h, thymidine was added again, and the cells were incubated for an additional 16 h. Plates were then washed, and fresh medium was added. The majority of cells were in G2/M phase 9 h later, as determined by fluorescence-activated cell sorting (FACS) analysis, and the cells were collected for study. For transfection, 293T or HeLa cells at 80% confluence were transfected with plasmids using Lipofectamine (Life Technologies) in serum-free medium. After 5 h of incubation, the medium was replaced with fresh complete medium. At 48 h post transfection, cells were subject to immunoblotting or immunofluorescence microscopy.

**Immunofluorescence microscopy**

Cells grown on coverslips were fixed in 4% formaldehyde in PBS at room temperature. The permeabilized cells were blocked with 10% normal horse serum plus 1% bovine serum albumin (BSA) for 1 h. A drop of the diluted monoclonal antibody against γ-tubulin (1:500 Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was placed on the coverslips overnight and then with Alexa 546 (red fluorescence)-conjugated goat anti-mouse secondary antibody (Life Technologies) for 1 h. The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, 1:1000 dilution) for 10 min. Images were acquired using a LEICA DC 500 camera on a microscope equipped with LEICA DMIRE2 fluorescent optics (Leica, Wetzlar, Germany).

**Flow cytometry**

HeLa cells were transfected with the pCMV-Myc vector, Myc-Aurora-A, or the two Myc-tagged mutants, and each plate was also transfected with the pBBl4 plasmid, which was 10% of the Aurora-A plasmids. At 48 h after transfection, the cells were washed in PBS and fixed in cold 70% ethanol overnight at 40°C. After another wash in PBS, cells were incubated with 50 mg/ml propidium iodide (Sigma-Aldrich, St. Louis, MO).
USA) and 100 mg/ml RNaseA (Sigma-Aldrich) for 30 min at room temperature. Fluorescence from the propidium iodide-DNA complex was measured using a FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), and the percentage of cells in each cell cycle phase was quantified using the ModFit program.

**ACKNOWLEDGEMENTS**

This work was supported by the National 973 Program and 863 High Technology Program of China, as well as the National Natural Science Foundation of China. We thank Dr. Meirong Bai, Dr. Auron A mutants' activities Meirong Bai, et al.

**REFERENCES**

1. Giet, R. and Prigent, C. (1999) Aurora/Plk1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. *J. Cell Sci.* **112**, 3591-3601.
2. Bischoff, J. R., Anderson, L., Zhu, Y., Mossie, K., Ng, L., Souza, B., Schryver, B., Flanagan, P., Clairvoyant, F., Ginthor, C., Chan, C. S., Novotny, M., Slamon, D. J., Plotman, G. D. (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. *EMBO J.* **17**, 3052-3065.
3. Kimura, M., Kotani, S., Hattori, T., Sumi, N., Yoshioka, T., Todoroko, K. and Okano, Y. (1997) Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to aurora of Drosophila and yeast Ipl 1. *J. Biol. Chem.* **272**, 13766-13771.
4. Littlepage, L. E., Wu, H., Andresson, T., Deanehan, J. K., Amundadottir, L. T., and Ruderman, J. V. (2002) Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 15440-15445.
5. Walter, A. O., Seghezzi, W., Korver, W., Sheung, J., and Lees, E. (2000) The mitotic serine/threonine kinase Aurora2/ AIK is regulated by phosphorylation and degradation. *Oncogene* **19**, 4906-4916.
6. Miyoshi, Y., Iwao, K., Egawa, C. and Noguchi, S. (2001) Association of centrosomal kinase STK15/ BTK kinase with chromosomal instability in human breast cancers. *Int. J. Cancer* **92**, 370-373.
7. Marumoto, T., Honda, S., Hara, T., Nitta, M., Hirota, T., Kohnura, E. and Saya, H. (2003) Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. *J. Biol. Chem.* **278**, 51786-51795.
8. Du, J. and Hannon, G. J. (2004) Suppression of p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 8973-8980.
9. Romé, P., Montembault, E., Franck, N., Pascal, A., Glover, D. M. and Giet, R. (2010) Aurora A contributes to p150 (glued) phosphorylation and function during mitosis. *J. Cell Biol.* **189**, 651-659.
10. Hirota, T., Kunitoku, N., Sasayama, T., Marumoto, T., Zhang, D. W., Nitta, M., Hatakeyama, K. and Saya, H. (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. *Cell* **114**, 585-598.
11. Pugacheva, E. N. and Golemis, E. A. (2005) The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. *Nat. Cell Biol.* **7**, 937-946.
12. Kufer, T. A., Silljé, H. H., Körner, R., Gruss, O. J., Meraldi, P. and Nigg, E. A. (2002) Human TPX2 is required for targeting Aurora-A kinase to the spindle. *J. Cell Biol.* **158**, 617-623.
13. Zhang, Y., Nii, J., Huang, Q., Ren, W., Yu, L. and Zhao, S. (2007) Identification of the auto-inhibitory domains of Aurora-A kinase. *Biochem. Biophys. Res. Commun.* **357**, 347-352.
14. Tsai, M. Y., Wiese, C., Cao, K., Martin, O., Donovan, P., Ruderman, J., Prigent, C. and Zheng, Y. (2003) A Ran signaling pathway mediated by the mitotic kinase Aurora A in spindle assembly. *Nat. Cell Biol.* **5**, 242-248.
15. Giet, R., McLean, D., Descamps, S., Lee, M. J., Raff, J. W., Prigent, C. and Glover D. M. (2002) Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. *J. Cell Biol.* **156**, 437-451.
16. Vander, G. and Lens, S. M. (2008) The Aurora kinase family in cell division and cancer. *Biochim. Biophys. Acta.* **1786**, 60-72.
17. Cheetham, G. M., Knegtel, R. M., Coll, J. T., Renwick, S. B., Swenson, L., Weber, P. and Lippke, J. A., et al. (2002) Crystal structure of Aurora-2, an oncogenic serine/threonine kinase. *J. Biol. Chem.* **277**, 42419-42422.
18. Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O. and Nakayama, T., et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. *Nat. Med.* **10**, 262-267.